Jpmorgan Chase & CO Uni Qure N.V. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Uni Qure N.V. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 453,784 shares of QURE stock, worth $6.01 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
453,784
Previous 395,538
14.73%
Holding current value
$6.01 Million
Previous $1.95 Million
310.92%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding QURE
# of Institutions
170Shares Held
42.5MCall Options Held
2.61MPut Options Held
582K-
Eco R1 Capital, LLC San Francisco, CA3.4MShares$45.1 Million2.81% of portfolio
-
Vestal Point Capital, LP New York, NY3.03MShares$40.1 Million3.17% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.45MShares$32.5 Million2.18% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.18MShares$28.8 Million0.56% of portfolio
-
Franklin Resources Inc San Mateo, CA1.99MShares$26.3 Million0.01% of portfolio
About uniQure N.V.
- Ticker QURE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,729,100
- Market Cap $619M
- Description
- uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...